ストックスクリーナーアプリを入手
14.01
5.21%
-0.77
プレマーケット:
14.05
0.04
+0.29%
前日終値:
$14.78
開ける：
$14.61
24時間の取引高:
613.47K
Relative Volume:
1.70
時価総額：
$240.94M
収益：
-
当期純損益:
$-52.60M
株価収益率:
-10.49
EPS:
-1.3361
ネットキャッシュフロー:
$-35.80M
1週間 パフォーマンス:
-6.91%
1か月 パフォーマンス:
+1.23%
6か月 パフォーマンス:
+100.72%
1年 パフォーマンス:
+158.01%
1日の値動き範囲:
$13.97
$14.92
1週間の範囲:
$13.94
$15.35
52週間の値動き範囲:
$4.63
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
14.01 | 254.18M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 開始されました | Piper Sandler | Overweight |
| 2024-10-24 | 開始されました | Leerink Partners | Outperform |
| 2024-10-14 | 開始されました | Guggenheim | Buy |
| 2024-09-30 | 開始されました | William Blair | Outperform |
| 2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 開始されました | MLV & Co | Buy |
| 2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
Panic Selling: Is Tenax Therapeutics Inc forming a double bottom2026 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
CEO Moves: Is Tenax Therapeutics Inc forming a double bottom2026 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Tenax Therapeutics Inc (TENX) - Stock Titan
TENX Options Volatility — NASDAQ:TENX - TradingView — Track All Markets
TENX Options Chain — NASDAQ:TENX - TradingView — Track All Markets
TENAX Therapeutics (NASDAQ: TENX) — Morgan Stanley reports 3.5%/3.4% positions - Stock Titan
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TENX Should I Buy - Intellectia AI
[EFFECT] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Volume Summary: What are Tenax Therapeutics Incs recent SEC filings showingOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX) - Seeking Alpha
Tenax Therapeutics (TENX): Cantor Fitzgerald Initiates Coverage with Overweight Rating | TENX Stock News - GuruFocus
Top Cypherpunk Technologies (CYPH) Competitors 2026 - MarketBeat
Published on: 2026-03-17 23:42:59 - baoquankhu1.vn
Tenax stock wins bullish view at Cantor (TENX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - MarketBeat
Tenax Therapeutics (TENX) Gains Momentum with Phase 3 Trial - GuruFocus
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX - MarketBeat
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | - gurufocus.com
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price - MarketBeat
What is Lifesci Capital's Forecast for TENX Q1 Earnings? - MarketBeat
What is Lifesci Capital’s Forecast for TENX Q1 Earnings? - Defense World
Trading Systems Reacting to (TENX) Volatility - Stock Traders Daily
Logos Global Management LP Acquires 615,000 Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Raised to "Strong-Buy" at Lifesci Capital - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026 - Meyka
Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates - AlphaStreet
Analysts Are Bullish on These Healthcare Stocks: Tenax Therapeutics (TENX), Esperion (ESPR) - The Globe and Mail
Christopher Giordano Discloses Investment at Tenax Therapeutics with 6.79% Stake - TradingView
Tenax Therapeutics (TENX) CEO reports 6.79% beneficial ownership stake - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
TENX: LEVEL trial enrollment completed early; global expansion and regulatory preparations advancing - TradingView
Tenax Therapeutics stock gains as trial enrollment complete By Investing.com - Investing.com Canada
Tenax Therapeutics Achieves Phase 3 LEVEL Study Patient Target and Reports 2025 Financial Results; Topline Data Expected Q3 2026 - Minichart
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):